NON-HODGKIN LYMPHOMA

This study is testing a drug called acalabrutinib, both by itself and combined with other cancer drugs, for adults whose B-cell non-Hodgkin lymphoma has come back or stopped responding to prior treatment. The main goals are to check the safety of these drug combinations and to se…

This study is testing whether adding low-dose radiation to an immunotherapy drug (pembrolizumab) can help control non-Hodgkin lymphoma that has come back or stopped responding to other treatments. It is for adults whose cancer has progressed after at least two prior therapies. Th…

This early-stage trial is testing a new version of CAR-T cell therapy called huCART19-IL18 for adults with certain blood cancers that have returned or not responded to standard treatments. The study aims to find a safe dose and see if the therapy can be reliably manufactured. It …

This is a first-in-human study to test the safety and early effects of a new type of cancer treatment called SC291. It is for adults with certain B-cell blood cancers (like non-Hodgkin lymphoma or chronic lymphocytic leukemia) that have come back or not responded to at least two …

This early-stage study is testing a new, faster way to make a personalized cell therapy for adults with B-cell non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. Doctors take a patient's own immune cells, modify them in a lab to better target cancer,…

This study is testing whether a shorter course of radiation treatment is safe for adults whose Hodgkin or non-Hodgkin lymphoma has returned or not responded to standard treatments. Instead of the usual 5-6 weeks of radiation, researchers aim to find the highest safe dose that can…

This study is testing if taking an oral drug called duvelisib after receiving CAR-T cell therapy can help the engineered immune cells survive longer in the body and work better. It will involve about 42 adults with certain types of lymphoma or leukemia who are already scheduled t…

This early-phase study is testing a new personalized treatment called CAR T-cell therapy for non-Hodgkin lymphoma that has returned or hasn't responded to standard treatments. Doctors collect a patient's own immune cells, modify them in a lab to better recognize and attack cancer…

This study tests a new treatment for cancers linked to the Epstein-Barr virus (EBV) that have come back or haven't responded to standard care. Doctors are using a bank of pre-made immune cells from healthy donors, which are specially trained to attack EBV-infected cancer cells, a…

This study is testing if adding a drug called vorinostat to standard medications can better prevent graft-versus-host disease (GVHD) in children and young adults getting a bone marrow transplant for blood cancers. GVHD is a serious complication where the donor's immune cells atta…

This study is for adults with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. It compares a new combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) against a standard chemotherapy regimen. The goal is to see if t…

This study allows a small group of lymphoma patients who have been successfully taking the experimental drug CC-122 for over five years in earlier trials to continue receiving it. The main goal is to monitor the long-term safety of the treatment for these specific patients. It is…

This early-stage study is testing an experimental drug called GNC-038 in adults with certain aggressive types of lymphoma that have returned or not responded to prior treatments. The main goals are to find a safe dose, check for side effects, and see if the drug can shrink tumors…

This early-stage study is testing whether immune cells from healthy donors, given along with two other drugs, are safe for people with advanced colorectal, stomach, or hard-to-treat blood cancers. The goal is to see if this combination helps the donor immune cells last longer in …

This study is testing a new type of cell therapy for patients with blood cancers or bone marrow diseases who need a stem cell transplant from a partially matched family donor. The goal is to see if adding specially treated immune cells, called 'veto cells,' can help the donor's c…

This early-stage study is testing whether giving a short course of radiation therapy before standard CAR-T cell treatment is safe and practical for people with B-cell lymphoma that has returned or not responded to other treatments. The goal is to see if this combined approach hel…

This early-stage trial is testing a new drug called WTX-330 in adults with advanced solid tumors or non-Hodgkin lymphoma that have stopped responding to standard treatments. The main goals are to find the safest and most effective dose and to see if the drug can shrink tumors. Re…

This study is testing a new, more convenient under-the-skin injection of an immunotherapy drug called mosunetuzumab for people with certain types of B-cell lymphoma. It aims to see if this method is safe, effective, and how the body handles the drug. The trial includes people wit…

This is an early-stage study testing the safety and dosing of a new experimental drug called GNC-038 in adults with aggressive blood cancers that have returned or not responded to standard treatments. The drug is a 'quad-specific antibody' designed to attack cancer cells by bindi…

This study is testing a new type of imaging scan to see if it can better detect and monitor tumors in children and young adults with cancer. The scan uses a radioactive form of a natural protein building block called methionine. Researchers want to see how well this new scan work…

This study is testing a new approach to prevent a common and dangerous viral infection called CMV in people receiving a stem cell transplant for blood cancer. Researchers are giving a vaccine to the healthy stem cell donors before the transplant. The goal is to see if the donor's…

This study is testing a vaccine designed to prevent cytomegalovirus (CMV) infection in adults with blood cancers who are receiving a half-matched stem cell transplant. CMV is a common virus that can become life-threatening when the immune system is weakened after transplant. The …

This study is testing whether adding acupuncture to standard pain care can help patients with multiple myeloma or lymphoma use fewer opioid medications during high-dose chemotherapy. Researchers are comparing two groups: one receiving acupuncture plus usual care, and one receivin…

This study aims to understand and track the long-term health problems that can develop in cancer survivors after their initial treatment is successful. It follows 500 adults who have finished treatment for certain cancers (like breast cancer, lymphoma, and leukemia) and are in re…

This study aims to understand how muscle strength and body composition affect recovery and long-term health in people with blood cancers who receive a stem cell transplant. Researchers will observe 144 patients to see if their muscle health at the time of transplant can predict c…

This study aims to understand why people who survive a blood cancer transplant have a higher risk of heart disease. Researchers will closely monitor 350 adult patients' heart, lung, and muscle function before their transplant and for two years after. The goal is to learn how thes…